SES
19.11.2021 08:52:13 CET | Business Wire | Press release
Residents of two remote Kazakhstan villages can now benefit from unprecedented Internet speeds via satellite-enabled Wi-Fi, through a network set up for 30 days by the leading global content connectivity solutions provider SES. The demo is implemented in cooperation with the Republican Center for Space Communications (RCSC ), a subsidiary of the Ministry of Digital Development, Innovations and Aerospace Industry and AsiaNetCom, a Kazakhstan-based connectivity provider. During the demonstration, the companies have achieved 380Mbps downlink and 120Mbps uplink via SES’s O3b satellite constellation, the highest speed ever recorded in Kazakhstan via satellite.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118006475/en/
The demo is done in the framework of the country’s national project called “Technological breakthrough via digitalisation, science and innovation”, that aims to bridge the digital divide and bring the benefits of high-performance communication networks for healthcare, businesses, local administrations, education and more.
As part of the collaboration agreement between SES and RCSC signed earlier this year, the test demonstrates the benefits of SES’s Medium Earth Orbit (MEO) networks and its upcoming second-generation O3b mPOWER communications system.
The current demo network is leveraging SES’s first-generation O3b satellites to connect an RCSC teleport located in Kokterek with the villages of Akterek and Beriktas for high-speed Internet access.
“Kazakhstan has already made progress in providing Internet connectivity to the population. However, there are still remote villages where it is impossible to deliver a network using radio relay communications or through cable connection. In those circumstances, we decided to use satellite constellations. This will allow us to expand our coverage and provide broadband Internet connection to the population of Kazakhstan”, said Bagdat Mussin, Minister of Digital Development, Innovations and Aerospace Industry (MDDIAI RK).
“The premise of national project “Technological breakthrough via digitalisation, science and innovation” is to bring the same quality of life and opportunities afforded by Internet access to every citizen of the country, wherever they live - in Nur-Sultan or in a remote mountain village. In some cases, the use of terrestrial networks is economically impractical, and we are considering the opportunities to implement innovative satellite technology to provide high-speed connectivity in those remote villages. The demo gives us an opportunity to explore the possibilities of further scaling”, said Malik Zhuiriktayev, Chairman of the Board of JSC RCSC.
“We are very excited to participate in this project, which aims to digitalise and to improve all spheres of life and economy in the country. Today in collaboration with our partners RCSC and AsiaNetCom, we have demonstrated the unrivalled performance of our innovative and proven MEO network by connecting rural Kazakhstan”, said Sandeep Jalan, Chief Financial Officer of SES. “When operational next year, our second-generation MEO system, O3b mPOWER, will further multiply the capacity delivered and bandwidth. In addition, it will deliver significantly higher speeds flexibly, catering to the increasing needs from governments, enterprises and mobile operators.”
Follow us on:
Twitter
Facebook
YouTube
LinkedIn
Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,500 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About RCSC
Joint Stock Company "Republican Center for Space Communication" was established by the Decree of the Government of the Republic of Kazakhstan in December 2003 on behalf of the First President of the Republic of Kazakhstan.
JSC "RCSC" is a subordinate enterprise of the Aerospace Committee of the Ministry of Digital Development, Innovation and Aerospace Industry of the Republic of Kazakhstan, the National Operator of the Space Communication System of Kazakhstan.
The Republican Center for Space Communications provides services for the provision of the transponder capacity of spacecraft (SC) of the KazSat series, monitoring of fixed satellite communication channels in the Ku-band on a geostationary arc from 13 to 130 E, as well as using the capabilities of the Teleport based on the Reserve ground-based spacecraft control complex and communication monitoring systems.
The resources of the KazSat series spacecraft made it possible to implement efficient and reliable satellite communication channels in the Republic of Kazakhstan. Spacecraft of the KazSat series, operated by RCKS JSC, provide great opportunities for telecommunications operators in Kazakhstan, national companies and holdings, government agencies and private companies for organizing digital TV and radio broadcasting (HD, DTH, IPTV), broadband Internet access, data transmission and creation of corporate satellite communication networks of various topologies.
Currently, JSC "RCSC" is one of the leading enterprises in the implementation of activities on communications in the telecommunications market of Kazakhstan.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118006475/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
